InVitria showcases animal-free recombinant albumins for biologics at IPEC Excipient World 2026

InVitria presented its recombinant human serum albumin (rHSA) products, Exbumin® and Optibumin® 25, at the IPEC Excipient World Biologics Summit 2026. These animal-origin-free proteins support stability and consistency in injectable biologics and vaccines, with proven use in approved medicines like Merck’s ERVEBO® Ebola vaccine. The products offer scalable, cGMP-compliant options for biologics manufacturers seeking reliable, plasma-free albumin excipients. CEO Scott Deeter highlighted the regulatory confidence and manufacturing scalability of their recombinant albumins, signaling growing adoption in advanced therapies.